You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Platinum

Showing 1 - 25 of 3,674
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Locally Advanced Hypopharyngeal Carcinoma Trial in Shanghai (drug, procedure, radiation)

Not yet recruiting
  • Locally Advanced Hypopharyngeal Carcinoma
  • three cycles (toripalimab + cetuximab + platinum)
  • +2 more
  • Shanghai, Shanghai, China
    Eye & ENT Hospital of Fudan University
Nov 22, 2023

Triple Negative Breast Cancer Trial in Dhaka (Doxorubicin, Cyclophosphamide, Paclitaxel)

Not yet recruiting
  • Triple Negative Breast Cancer
  • Dhaka, Bangladesh
    Bangabandhu Sheikh Mujib Medical University
May 24, 2023

NSCLC Trial in Tianjing (Envalfolimab subcutaneously injected+Platinum-based doublet chemo intravenous injection,

Not yet recruiting
  • Non-small Cell Lung Cancer
  • Envalfolimab subcutaneously injected+Platinum-based doublet chemotherapy intravenous injection
  • placebo subcutaneously injected +Platinum-based doublet chemotherapy intravenous injection
  • Tianjing, Tianjin, China
    Tianjin cancer hospital
Nov 3, 2023

Esophageal Squamous Carcinoma, HER-2 Protein Overexpression Trial (RC48+PD-1+platinum-based)

Not yet recruiting
  • Esophageal Squamous Carcinoma
  • HER-2 Protein Overexpression
  • (no location specified)
Sep 24, 2023

Ovarian Cancer, Platinum-resistant Ovarian Cancer Trial in Minsk (Gemcitabine, ELENAGEN)

Active, not recruiting
  • Ovarian Cancer
  • Platinum-resistant Ovarian Cancer
  • Minsk, Belarus
    Minsk City Clinical Oncology Center
Jul 27, 2023

Deep Vein Thrombosis, Venous Thromboembolism, Pulmonary Embolism Trial (Celect Platinum Vena Cava Filter)

Not yet recruiting
  • Deep Vein Thrombosis
  • +2 more
  • Celect Platinum Vena Cava Filter
  • (no location specified)
May 30, 2023

NSCLC (NSCLC) Trial (Sotorasib, Pembrolizumab)

Not yet recruiting
  • Non-Small Cell Lung Cancer (NSCLC)
  • (no location specified)
Jun 26, 2023

Platinum-resistant Ovarian Cancer

Not yet recruiting
  • Ovarian Cancer
  • pegylated liposomal doxorubicin
  • (no location specified)
Aug 2, 2023

GSTP1 and Other Gene Polymorphisms With Platinum-induced

Not yet recruiting
  • Non-small Cell Lung Cancer
  • GSTP1 A313G （AA）
  • (no location specified)
Nov 16, 2023

Platinum-resistant Ovarian Cancer, Platinum-refractory Ovarian Cancer, Fallopian Tube Cancer Trial in Orlando, Albuquerque

Recruiting
  • Platinum-resistant Ovarian Cancer
  • +6 more
  • olvimulogene nanivacirepvec
  • +3 more
  • Orlando, Florida
    AdventHealth Cancer Institute
Sep 1, 2022

Ovarian Cancer Recurrent Trial (Fluzopril Combined With Apatinib)

Not yet recruiting
  • Ovarian Cancer Recurrent
  • Fluzopril Combined With Apatinib
  • (no location specified)
Oct 22, 2023

Advanced Solid Tumor, Platinum-resistant Ovarian Cancer Trial (SON-1010)

Not yet recruiting
  • Advanced Solid Tumor
  • Platinum-resistant Ovarian Cancer
  • SON-1010
  • (no location specified)
Mar 10, 2023

Ovarian High Grade Serous Adenocarcinoma, Platinum-Resistant Ovarian Carcinoma Trial in Atlanta (Atovaquone, Biopsy, Computed

Not yet recruiting
  • Ovarian High Grade Serous Adenocarcinoma
  • Platinum-Resistant Ovarian Carcinoma
  • Atlanta, Georgia
    Emory University Hospital/Winship Cancer Institute
Aug 11, 2023

Platinum-resistant Ovarian Cancer Trial in Shanghai (Oral Topotecan Combined With Anlotinib)

Not yet recruiting
  • Platinum-resistant Ovarian Cancer
  • Oral Topotecan Combined With Anlotinib
  • Shanghai, China
    Xinhua Hospital Affiliated to Shanghai Jiaotong University Schoo
Feb 12, 2023

Gynecologic Cancer Trial (Experimental product - Fortifit® Powder, Standard of care)

Not yet recruiting
  • Gynecologic Cancer
  • Experimental product - Fortifit® Powder
  • Standard of care
  • (no location specified)
Oct 14, 2023

Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal

Not yet recruiting
  • Platinum-Resistant Fallopian Tube Carcinoma
  • +5 more
  • Biopsy
  • +4 more
  • Duarte, California
    City of Hope Medical Center
Jan 3, 2023

Cancer, Ototoxicity, Drug-Induced, Quality of Life Trial (Patients suffering from chemo-induced ototoxicity)

Not yet recruiting
  • Cancer
  • +3 more
  • Patients suffering from chemotherapy-induced ototoxicity
  • (no location specified)
Jun 29, 2023

Small Cell Lung Cancer Extensive Stage Trial (Pembrolizumab, Plinabulin plus Etoposide and Platinum)

Not yet recruiting
  • Small Cell Lung Cancer Extensive Stage
  • Pembrolizumab, Plinabulin plus Etoposide and Platinum
  • (no location specified)
Feb 15, 2023

Non-squamous NSCLC Trial in Nanjing (paclitaxel polymeric micelles for injection)

Not yet recruiting
  • Non-squamous NSCLC
  • paclitaxel polymeric micelles for injection
  • Nanjing, Jiangsu, China
  • +1 more
Mar 13, 2023

Lung Adenocarcinoma Trial in Shijiazhuang (Tislelizumab,Platinum)

Recruiting
  • Lung Adenocarcinoma
  • Shijiazhuang, Hebei, China
    The Fourth Hospital of Hebei Medical University (Hebei Tumor Hos
Sep 24, 2023

Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, PARP Inhibitor Trial in Pittsburgh

Not yet recruiting
  • Platinum-Resistant Fallopian Tube Carcinoma
  • +3 more
  • Pittsburgh, Pennsylvania
    UPMC Hillman Cancer Center
Sep 8, 2022

NSCLC Trial (Durvalumab, Tremelimumab, Pemetrexed)

Not yet recruiting
  • Carcinoma, Non-Small-Cell Lung
  • (no location specified)
Aug 17, 2023

NSCLC Trial in Worldwide (RO7247669, Pembrolizumab, Paclitaxel)

Recruiting
  • Non-small Cell Lung Cancer
  • Benowa, Queensland, Australia
  • +6 more
Mar 16, 2023

Nasopharyngeal Carcinoma Trial (procedure, drug, biological)

Not yet recruiting
  • Nasopharyngeal Carcinoma
  • Biospecimen Collection
  • +9 more
  • (no location specified)
Sep 12, 2023

Recurrent Ovarian Cancer Trial in Pittsburgh (CPI-0209, carboplatin)

Not yet recruiting
  • Recurrent Ovarian Cancer
  • Pittsburgh, Pennsylvania
    Magee-Womens Research Institute / UPMC Magee Womens Hospital
Jul 3, 2023